MeiraGTx (MGTX) Stock Price, News & Analysis

Company Overview

MeiraGTx Holdings plc (NASDAQ:MGTX) is a clinical-stage biotechnology company developing gene therapy and ribonucleic acid (RNA) medicines for diseases with significant unmet medical needs. Its research focuses primarily on the central nervous system, immune-mediated conditions and disorders affecting salivary gland function.

The company’s technology platforms are designed to deliver therapeutic genes or regulate gene expression in targeted tissues. Its investigational programs have included gene therapies for Parkinson’s disease and radiation-induced xerostomia, a condition involving chronic dry mouth after cancer treatment. MeiraGTx has also pursued additional programs in neurological and other serious diseases, although its pipeline and development priorities may change as clinical studies progress.

Founded in 2015, MeiraGTx has built research, development and manufacturing capabilities in the United States and the United Kingdom. The company is led by Alexandra Forbes, who co-founded MeiraGTx and serves as president and chief executive officer.

Key Stats

• Today's Range: $9.38 to $9.93
• 50-Day Range: $9.41 to $14.97
• 52-Week Range: $6.62 to $15.35
• Volume: 836,396 shs
• Average Volume: 758,293 shs
• Market Capitalization: $949.87 million
• P/E Ratio: 13.93
• Dividend Yield: N/A
• Price Target: $24.71
• Consensus Rating: Moderate Buy

MeiraGTx Stock Analysis - MarketRank™

MeiraGTx scored higher than 57% of companies evaluated by MarketBeat, and ranked 426th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

MeiraGTx has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 5 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

MeiraGTx has a consensus price target of $24.71, representing about 149.9% upside from its current price of $9.89.

Amount of Analyst Coverage

MeiraGTx has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MeiraGTx are expected to decrease in the coming year, from $0.30 to ($2.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MeiraGTx is 13.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.86.

Price to Earnings Ratio vs. Sector

The P/E ratio of MeiraGTx is 13.93, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.95.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.74% of the float of MeiraGTx has been sold short.

Short Interest Ratio / Days to Cover

MeiraGTx has a short interest ratio ("days to cover") of 5.04.

Change versus previous month

Short interest in MeiraGTx has recently increased by 49.48%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MeiraGTx does not currently pay a dividend.

Dividend Growth

MeiraGTx does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.37

News Sentiment

MeiraGTx has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for MeiraGTx this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, MeiraGTx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,854,172.00 in company stock.

Percentage Held by Insiders

7.40% of the stock of MeiraGTx is held by insiders.

Percentage Held by Institutions

67.48% of the stock of MeiraGTx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MGTX
• CIK: 1735438
• Web: www.meiragtx.com
• Phone: (646) 860-7985
• Fax: N/A
• Employees: 393
• Year Founded: 2015

Price Target and Rating

• Average Price Target for MeiraGTx: $24.71
• High Price Target: $35.00
• Low Price Target: $16.00
• Potential Upside/Downside: +149.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.71
• Trailing P/E Ratio: 13.93
• Forward P/E Ratio: 32.97
• P/E Growth: N/A
• Net Income: -$114.20 million
• Net Margins: 19.87%
• Pretax Margin: 20.45%
• Return on Equity: 283.85%
• Return on Assets: 29.39%

Debt

• Debt-to-Equity Ratio: 0.46
• Current Ratio: 3.76
• Quick Ratio: 3.76

Sales & Book Value

• Annual Sales: $397.50 million
• Price / Sales: 2.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: -141.29

Miscellaneous

• Outstanding Shares: 96,043,000
• Free Float: 88,936,000
• Market Cap: $949.87 million
• Optionable: Optionable
• Beta: 1.35